EGFR and non-small cell lung carcinoma: The FDA approved gefitinib for advanced NSCLC progressing beyond platinum doublet chemotherapy and docetaxel on 5 May 2003 and, since 13 July 2015, it has been expanded for use as a first line treatment in metastatic NSCLC with the EGFR mutations listed above [26].